In patients with HCC, a loss of SHP2 expression was associated with suppressed NF-κB–SHP2–ERK pathway activity and accelerated HCC development, whereas SHP2 overexpression in parallel with increased STAT3 activity was associated with fibrosis promotion during the early stages of HCC development. Here, NFKB1 is linked to hepatocellular carcinoma.